BioGenCell Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://biogencell.net
Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
Phase 1
Active, not recruiting
- Conditions
- Chronic Limb-Threatening IschemiaPeripheral Arterial DiseasePeripheral Vascular Disease
- Interventions
- Biological: Control mediumBiological: BGC101 (autologous EnEPC preparation)
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BioGenCell Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02805023
- Locations
- 🇺🇸
University of San Francisco, San Francisco, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
News
No news found